A Phenomenology-Based Approach to Inborn Errors of Metabolism with Spasticity

Chapter 10 - A Phenomenology-Based Approach to Inborn Errors of Metabolism with Spasticity

from Section I - General Principles and a Phenomenology-Based Approach to Movement Disorders and Inherited Metabolic Disorders

Published online by Cambridge University Press: 24 September 2020

Laura Tochen and

Toni S. Pearson

Edited by

Darius Ebrahimi-Fakhari and

Phillip L. Pearl

Show author details

Darius Ebrahimi-Fakhari: Affiliation:
Harvard Medical School
Phillip L. Pearl: Affiliation:
Harvard Medical School

Book contents

Get access

Summary

Spasticity is a motor abnormality characterized by increased muscular tone. It results from a lesion of the corticospinal (or pyramidal) tract, which includes motor neurons in the cerebral cortex and their axonal white matter projections through the brain and spinal cord, to the point of synapse with lower motor neurons in the spinal cord. Patients with spasticity, or their caregivers, typically complain of stiffness, and the predominant associated examination findings are a velocity-dependent resistance to passive movement of an affected limb, hyperreflexia, and pathological reflexes such as a Babinski sign. Spasticity is typically accompanied by weakness and impaired motor control in affected muscle groups. Depending on the site of the lesion in the central nervous system, spasticity may be present in both legs (termed diparesis or paraparesis), all four limbs (quadriparesis or tetraparesis), or one side of the body (hemiparesis).

Type: Chapter
Information: Movement Disorders and Inherited Metabolic Disorders
Recognition, Understanding, Improving Outcomes
, pp. 143 - 154

DOI: https://doi.org/10.1017/9781108556767 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2020

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

Sedel, F, Fontaine, B, Saudubray, JM, Lyon-Caen, O. Hereditary spastic paraparesis in adults associated with inborn errors of metabolism: A diagnostic approach. J Inherit Metab Dis. 2007;30(6):855–64.Google Scholar

Martinelli, D, Diodato, D, Ponzi, E, et al. The hyperornithinemia–hyperammonemia–homocitrullinuria syndrome. Orphanet J Rare Dis. 2015;10:29.CrossRef Google Scholar PubMed

Huemer, M, Diodato, D, Schwahn, B, et al. Guidelines for diagnosis and management of the cobalamin-related remethylation disorders cblC, cblD, cblE, cblF, cblG, cblJ and MTHFR deficiency. J Inherit Metab Dis. 2017;40(1):21–48.Google Scholar

Wolf, B. The neurology of biotinidase deficiency. Mol Genet Metab. 2011;104(1–2):27–34.Google Scholar

Chedrawi, AK, Ali, A, Al Hassnan, ZN, Faiyaz-Ul-Haque, M, Wolf, B. Profound biotinidase deficiency in a child with predominantly spinal cord disease. J Child Neurol. 2008;23(9):1043–8.CrossRef Google Scholar

Ramaekers, VT, Brab, M, Rau, G, Heimann, G. Recovery from neurological deficits following biotin treatment in a biotinidase Km variant. Neuropediatrics. 1993;24(2):98–102.CrossRef Google Scholar

Ramaekers, V, Sequeira, JM, Quadros, EV. Clinical recognition and aspects of the cerebral folate deficiency syndromes. Clin Chem Lab Med. 2013;51(3):497–511.CrossRef Google Scholar PubMed

Federico, A, Dotti, MT, Gallus, GN. Cerebrotendinous xanthomatosis. GeneReviews®. 2003;Jul 16 (updated Apr 14, 2016).Google Scholar

Wong, JC, Walsh, K, Hayden, D, Eichler, FS. Natural history of neurological abnormalities in cerebrotendinous xanthomatosis. J Inherit Metab Dis. 2018;41(4):647–56.Google Scholar

Abe, R, Sekijima, Y, Kinoshita, T, et al. Spinal form cerebrotendinous xanthomatosis patient with long spinal cord lesion. J Spinal Cord Med. 2016;39(6):726–9.Google Scholar

McCombe, PA, McLaughlin, DB, Chalk, JB, et al. Spasticity and white matter abnormalities in adult phenylketonuria. J Neurol Neurosurg Psychiatry. 1992;55(5):359–61.Google Scholar

Atwal, PS, Scaglia, F. Molybdenum cofactor deficiency. Mol Genet Metab. 2016;117(1):1–4.Google Scholar

Duffner, PK, Barczykowski, A, Jalal, K, et al. Early infantile Krabbe disease: Results of the World-Wide Krabbe Registry. Pediatr Neurol. 2011;45(3):141–8.Google Scholar

Duffner, PK, Jalal, K, Carter, RL. The Hunter’s Hope Krabbe family database. Pediatr Neurol. 2009;40(1):13–8.Google Scholar

Abdelhalim, AN, Alberico, RA, Barczykowski, AL, Duffner, PK. Patterns of magnetic resonance imaging abnormalities in symptomatic patients with Krabbe disease correspond to phenotype. Pediatr Neurol. 2014;50(2):127–34.CrossRef Google Scholar PubMed

Husain, AM, Altuwaijri, M, Aldosari, M. Krabbe disease: Neurophysiologic studies and MRI correlations. Neurology. 2004;63(4):617–20.Google Scholar

Wright, MD, Poe, MD, DeRenzo, A, Haldal, S, Escolar, ML. Developmental outcomes of cord blood transplantation for Krabbe disease: A 15-year study. Neurology. 2017;89(13):1365–72.Google Scholar

Mahmood, A, Berry, J, Wenger, DA, Escolar, M, Sobeih, M, Raymond, G, et al. Metachromatic leukodystrophy: A case of triplets with the late infantile variant and a systematic review of the literature. J Child Neurol. 2010;25(5):572–80.Google Scholar

Cameron, CL, Kang, PB, Burns, TM, Darras, BT, Jones, HR, Jr. Multifocal slowing of nerve conduction in metachromatic leukodystrophy. Muscle Nerve. 2004;29(4):531–6.Google Scholar

Eichler, F, Grodd, W, Grant, E, et al. Metachromatic leukodystrophy: A scoring system for brain MR imaging observations. AJNR Am J Neuroradiol. 2009;30(10):1893–7.CrossRef Google Scholar PubMed

van Rappard, DF, Bugiani, M, Boelens, JJ, et al. Gallbladder and the risk of polyps and carcinoma in metachromatic leukodystrophy. Neurology. 2016;87(1):103–11.Google Scholar

Groeschel, S, Kuhl, JS, Bley, AE, et al. Long-term outcome of allogeneic hematopoietic stem cell transplantation in patients with juvenile metachromatic leukodystrophy compared with nontransplanted control patients. JAMA Neurol. 2016;73(9):1133–40.Google Scholar

Ahrens-Nicklas, R, Schlotawa, L, Ballabio, A, et al. Complex care of individuals with multiple sulfatase deficiency: Clinical cases and consensus statement. Mol Genet Metab. 2018;123(3):337–46.CrossRef Google Scholar PubMed

Brunetti-Pierri, N, Scaglia, F. GM1 gangliosidosis: Review of clinical, molecular, and therapeutic aspects. Mol Genet Metab. 2008;94(4):391–6.Google Scholar

Steenweg, ME, Vanderver, A, Blaser, S, et al. Magnetic resonance imaging pattern recognition in hypomyelinating disorders. Brain. 2010;133(10):2971–82.Google Scholar

Roze, E, Paschke, E, Lopez, N, et al. Dystonia and parkinsonism in GM1 type 3 gangliosidosis. Mov Disord. 2005;20(10):1366–9.Google Scholar

Deodato, F, Procopio, E, Rampazzo, A, et al. The treatment of juvenile/adult GM1-gangliosidosis with miglustat may reverse disease progression. Metab Brain Dis. 2017;32(5):1529–36.Google Scholar

Smith, NJ, Winstone, AM, Stellitano, L, Cox, TM, Verity, CM. GM2 gangliosidosis in a UK study of children with progressive neurodegeneration: 73 cases reviewed. Dev Med Child Neurol. 2012;54(2):176–82.Google Scholar

Maegawa, GH, Stockley, T, Tropak, M, et al. The natural history of juvenile or subacute GM2 gangliosidosis: 21 new cases and literature review of 134 previously reported. Pediatrics. 2006;118(5):e1550-62.CrossRef Google Scholar PubMed

Frey, LC, Ringel, SP, Filley, CM. The natural history of cognitive dysfunction in late-onset GM2 gangliosidosis. Arch Neurol. 2005;62(6):989–94.Google Scholar

Willems, PJ, Gatti, R, Darby, JK, et al. Fucosidosis revisited: A review of 77 patients. Am J Med Genet. 1991;38(1):111–31.CrossRef Google Scholar PubMed

Moser, HW, Raymond, GV, Dubey, P. Adrenoleukodystrophy: New approaches to a neurodegenerative disease. JAMA. 2005;294(24):3131–4.Google Scholar

Loes, DJ, Fatemi, A, Melhem, ER, et al. Analysis of MRI patterns aids prediction of progression in X-linked adrenoleukodystrophy. Neurology. 2003;61(3):369–74.Google Scholar

Mahmood, A, Raymond, GV, Dubey, P, Peters, C, Moser, HW. Survival analysis of haematopoietic cell transplantation for childhood cerebral X-linked adrenoleukodystrophy: A comparison study. Lancet Neurol. 2007;6(8):687–92.Google Scholar

Engelen, M, Barbier, M, Dijkstra, IM, et al. X-linked adrenoleukodystrophy in women: A cross-sectional cohort study. Brain. 2014;137(Pt 3):693–706.Google Scholar

Steinberg, SJ, Dodt, G, Raymond, GV, et al. Peroxisome biogenesis disorders. Biochim Biophys Acta. 2006;1763(12):1733–48.Google Scholar

Ebberink, MS, Csanyi, B, Chong, WK, et al. Identification of an unusual variant peroxisome biogenesis disorder caused by mutations in the PEX16 gene. J Med Genet. 2010;47(9):608–15.Google Scholar

Patel, KP, O’Brien, TW, Subramony, SH, Shuster, J, Stacpoole, PW. The spectrum of pyruvate dehydrogenase complex deficiency: Clinical, biochemical and genetic features in 371 patients. Mol Genet Metab. 2012;106(3):385–94.Google Scholar

Cross, JH, Connelly, A, Gadian, DG, et al. Clinical diversity of pyruvate dehydrogenase deficiency. Pediatr Neurol. 1994;10(4):276–83.Google Scholar

Boczonadi, V, Jennings, MJ, Horvath, R. The role of tRNA synthetases in neurological and neuromuscular disorders. FEBS Lett. 2018;592(5):703–17.Google Scholar

Diodato, D, Ghezzi, D, Tiranti, V. The mitochondrial aminoacyl tRNA synthetases: Genes and syndromes. Int J Cell Biol. 2014;2014:787956.Google Scholar

Bayat, V, Thiffault, I, Jaiswal, M, et al. Mutations in the mitochondrial methionyl-tRNA synthetase cause a neurodegenerative phenotype in flies and a recessive ataxia (ARSAL) in humans. PLoS Biol. 2012;10(3):e1001288.Google Scholar

Matalon, RM, Michals-Matalon, K. Spongy degeneration of the brain, Canavan disease: Biochemical and molecular findings. Front Biosci. 2000;5:D307-11.Google Scholar

Hennermann, JB, Berger, JM, Grieben, U, Scharer, G, Van Hove, JL. Prediction of long-term outcome in glycine encephalopathy: A clinical survey. J Inherit Metab Dis. 2012;35(2):253–61.Google Scholar

Steiman, GS, Yudkoff, M, Berman, PH, Blazer-Yost, B, Segal, S. Late-onset nonketotic hyperglycinemia and spinocerebellar degeneration. J Pediatr. 1979;94(6):907–11.Google Scholar

Bank, WJ, Morrow, G, 3rd. A familial spinal cord disorder with hyperglycinemia. Arch Neurol. 1972;27(2):136–44.Google Scholar

Chiong, MA, Procopis, P, Carpenter, K, Wilcken, B. Late-onset nonketotic hyperglycinemia with leukodystrophy and an unusual clinical course. Pediatr Neurol. 2007;37(4):283–6.Google Scholar

van der Crabben, SN, Verhoeven-Duif, NM, Brilstra, EH, et al. An update on serine deficiency disorders. J Inherit Metab Dis. 2013;36(4):613–9.Google Scholar

de Koning, TJ, Jaeken, J, Pineda, M, et al. Hypomyelination and reversible white matter attenuation in 3-phosphoglycerate dehydrogenase deficiency. Neuropediatrics. 2000;31(6):287–92.Google Scholar

Ruzzo, EK, Capo-Chichi, JM, Ben-Zeev, B, et al. Deficiency of asparagine synthetase causes congenital microcephaly and a progressive form of encephalopathy. Neuron. 2013;80(2):429–41.Google Scholar

Alfadhel, M, Alrifai, MT, Trujillano, D, et al. Asparagine synthetase deficiency: New inborn errors of metabolism. JIMD Rep. 2015;22:11–6.Google Scholar

Fraser, JL, Venditti, CP. Methylmalonic and propionic acidemias: Clinical management update. Curr Opin Pediatr. 2016;28(6):682–93.Google Scholar

Cherin, P, Rose, C, de Roux-Serratrice, C, et al. The neurological manifestations of Gaucher disease type 1: The French Observatoire on Gaucher disease (FROG). J Inherit Metab Dis. 2010;33(4):331–8.Google Scholar

Mignot, C, Doummar, D, Maire, I, De Villemeur, TB, French Type 2 Gaucher Disease Study Group. Type 2 Gaucher disease: 15 new cases and review of the literature. Brain Dev. 2006;28(1):39–48.Google Scholar

Roshan Lal, T, Sidransky, E. The spectrum of neurological manifestations associated with Gaucher disease. Diseases. 2017;5(1).Google Scholar

Nagappa, M, Bindu, PS, Taly, AB, Sinha, S. Oculomotor apraxia in Gaucher disease. Pediatr Neurol. 2015;52(4):468–9.Google Scholar

Perucca, G, Soares, BP, Stagliano, S, et al. Thalamic and dentate nucleus abnormalities in the brain of children with Gaucher disease. Neuroradiology. 2018;60(12):1353–6.Google Scholar

Weiss, K, Gonzalez, A, Lopez, G, et al. The clinical management of type 2 Gaucher disease. Mol Genet Metab. 2015;114(2):110–22.Google Scholar

Hogarth, P, Kurian, MA, Gregory, A, et al. Consensus clinical management guideline for pantothenate kinase-associated neurodegeneration (PKAN). Mol Genet Metab. 2017;120(3):278–87.Google Scholar

Illingworth, MA, Meyer, E, Chong, WK, et al. PLA2G6-associated neurodegeneration (PLAN): Further expansion of the clinical, radiological and mutation spectrum associated with infantile and atypical childhood-onset disease. Mol Genet Metab. 2014;112(2):183–9.Google Scholar

Fuijkschot, J, Theelen, T, Seyger, MM, van der Graaf, M, de Groot, IJ, Wevers, RA, et al. Sjögren–Larsson syndrome in clinical practice. J Inherit Metab Dis. 2012;35(6):955–62.Google Scholar